<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Current Computer-Aided Drug Design</journal-id><journal-title-group><journal-title xml:lang="en">Current Computer-Aided Drug Design</journal-title><trans-title-group xml:lang="ru"><trans-title>Current Computer-Aided Drug Design</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1573-4099</issn><issn publication-format="electronic">1875-6697</issn><publisher><publisher-name xml:lang="en">Bentham Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">644149</article-id><article-id pub-id-type="doi">10.2174/1573409919666230509123852</article-id><article-categories><subj-group subj-group-type="toc-heading"><subject>Chemistry</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Synthesis, Molecular Modeling and Biological Evaluation of Novel Trifluoromethyl Benzamides as Promising CETP Inhibitors</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Abu Khalaf</surname><given-names>Reema</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Abusaad</surname><given-names>Amani</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Al-Nawaiseh</surname><given-names>Bara'a</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Sabbah</surname><given-names>Dima</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Albadawi</surname><given-names>Ghadeer</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1"><institution>Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan</institution></aff><aff id="aff2"><institution>Department of Pharmacy, Al-Zaytoonah University of Jordan</institution></aff><pub-date date-type="pub" iso-8601-date="2024-05-01" publication-format="electronic"><day>01</day><month>05</month><year>2024</year></pub-date><volume>20</volume><issue>5</issue><issue-title xml:lang="ru"/><fpage>564</fpage><lpage>574</lpage><history><date date-type="received" iso-8601-date="2025-01-07"><day>07</day><month>01</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Bentham Science Publishers</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Bentham Science Publishers</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://rjeid.com/1573-4099/article/view/644149">https://rjeid.com/1573-4099/article/view/644149</self-uri><abstract xml:lang="en"><p id="idm46041443814800">Background:Hyperlipidemia is considered a major risk factor for the progress of atherosclerosis.</p><p id="idm46041443818800">Objective:Cholesteryl ester transfer protein (CETP) facilitates the relocation of cholesterol esters from HDL to LDL. CETP inhibition produces higher HDL and lower LDL levels.</p><p id="idm46041443822768">Methods:Synthesis of nine benzylamino benzamides 8a-8f and 9a-9c was performed.</p><p id="idm46041443827824">Results:In vitro biological study displayed potential CETP inhibitory activity, where compound 9c had the best activity with an IC50 of 1.03 µM. Induced-fit docking demonstrated that 8a-8f and 9a-9c accommodated the CETP active site and hydrophobic interaction predominated ligand/ CETP complex formation.</p><p id="idm46041443837200">Conclusion::Pharmacophore mapping showed that this scaffold endorsed CETP inhibitors features and consequently elaborated the high CETP binding affinity.</p></abstract><kwd-group xml:lang="en"><kwd>CETP inhibitors</kwd><kwd>hyperlipidemia</kwd><kwd>induced-fit docking</kwd><kwd>pharmacophore mapping</kwd><kwd>trifluoromethyl benzamides</kwd><kwd>molecular docking.</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Beheshti, S.; Madsen, C.M.; Varbo, A.; Benn, M.; Nordestgaard, B.G. Relationship of familial hypercholesterolemia and high LDL cholesterol to ischemic stroke: The copenhagen general population study. Circulation, 2018, 138(6), 578-589. doi: 10.1161/CIRCULATIONAHA.118.033470 PMID: 29593013</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Blauw, L.L.; Noordam, R.; Soidinsalo, S.; Blauw, C.A.; Li-Gao, R.; de Mutsert, R.; Berbée, J.F.P.; Wang, Y.; van Heemst, D.; Rosendaal, F.R.; Jukema, J.W.; Mook-Kanamori, D.O.; Würtz, P.; Willems van Dijk, K.; Rensen, P.C.N. Mendelian randomization reveals unexpected effects of CETP on the lipoprotein profile. Eur. J. Hum. Genet., 2019, 27(3), 422-431. doi: 10.1038/s41431-018-0301-5 PMID: 30420679</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Kobayashi, J. Which is the best predictor for the development of atherosclerosis among circulating lipoprotein lipase, Hepatic lipase, and endothelial lipase? J. Atheroscler. Thromb., 2019, 26(9), 758-759. doi: 10.5551/jat.ED108 PMID: 30814386</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Jarab, A.S.; Alefishat, E.A.; Al-Qerem, W.; Mukattash, T.L.; Al-Hajjeh, D.M. Lipid control and its associated factors among patients with dyslipidaemia in Jordan. Int. J. Clin. Pract., 2021, 75(5), e14000. doi: 10.1111/ijcp.14000 PMID: 33400313</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Gou, L.; Jin, T.; Chen, S.; Li, N.; Hao, D.; Zhang, S.; Zhang, L. Bio-macromolecular dynamic structures and functions, illustrated with DNA, antibody, and lipoprotein. Chin. Phys. B, 2018, 27(2), 028708. doi: 10.1088/1674-1056/27/2/028708</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Maugeais, C.; Perez, A.; von der Mark, E.; Magg, C.; Pflieger, P.; Niesor, E.J. Evidence for a role of CETP in HDL remodeling and cholesterol efflux: Role of cysteine 13 of CETP. Biochim. Biophys. Acta Mol. Cell Biol. Lipids, 2013, 1831(11), 1644-1650. doi: 10.1016/j.bbalip.2013.07.007 PMID: 23872476</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Dergunov, A.D.; Shabrova, E.V.; Dobretsov, G.E. Cholesteryl ester diffusion, location and self-association constraints determine CETP activity with discoidal HDL: Excimer probe study. Arch. Biochem. Biophys., 2014, 564, 211-218. doi: 10.1016/j.abb.2014.09.019 PMID: 25449063</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Suhy, A.; Hartmann, K.; Newman, L.; Papp, A.; Toneff, T.; Hook, V.; Sadee, W. Genetic variants affecting alternative splicing of human cholesteryl ester transfer protein. Biochem. Biophys. Res. Commun., 2014, 443(4), 1270-1274. doi: 10.1016/j.bbrc.2013.12.127 PMID: 24393849</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Liu, S.; Mistry, A.; Reynolds, J.M.; Lloyd, D.B.; Griffor, M.C.; Perry, D.A.; Ruggeri, R.B.; Clark, R.W.; Qiu, X. Crystal structures of cholesteryl ester transfer protein in complex with inhibitors. J. Biol. Chem., 2012, 287(44), 37321-37329. doi: 10.1074/jbc.M112.380063 PMID: 22961980</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Abu Khalaf, R.; Abu Sheikha, G.; Bustanji, Y.; Taha, M.O. Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration. Eur. J. Med. Chem., 2010, 45(4), 1598-1617. doi: 10.1016/j.ejmech.2009.12.070 PMID: 20116902</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Sheikha, G.A.; Abu Khalaf, R.; Melhem, A.; Albadawi, G. Design, synthesis, and biological evaluation of benzylamino-methanone based cholesteryl ester transfer protein inhibitors. Molecules, 2010, 15(8), 5721-5733. doi: 10.3390/molecules15085721 PMID: 20724961</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Abu Khalaf, R.; Abu Sheikha, G.; Al-Shaer, M.; Albadawi, G.; Taha, M. Design, synthesis, and biological evaluation of sulfonic acid ester and benzenesulfonamide derivatives as potential CETP inhibitors. Med. Chem. Res., 2012, 21(11), 3669-3680. doi: 10.1007/s00044-011-9917-5</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Abu Khalaf, R.; Abd El-Aziz, H.; Sabbah, D.; Albadawi, G.; Abu Sheikha, G. CETP inhibitory activity of chlorobenzyl benzamides: QPLD docking, pharmacophore mapping and synthesis. Lett. Drug Des. Discov., 2017, 14(12), 1391-1400. doi: 10.2174/1570180814666170412122304</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Abu Khalaf, R.; Al-Rawashdeh, S.; Sabbah, D.; Abu Sheikha, G. Molecular docking and pharmacophore modeling studies of fluorinated benzamides as potential CETP inhibitors. Med. Chem., 2017, 13(3), 239-253. doi: 10.2174/1573406412666161104121042 PMID: 27823564</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Abu Khalaf, R.; Sabbah, D.; Al-Shalabi, E.; Bishtawi, S.; Albadawi, G.; Abu Sheikha, G. synthesis, biological evaluation, and molecular modeling study of substituted benzyl benzamides as CETP inhibitors. Arch. Pharm., 2017, 350(12), 1700204. doi: 10.1002/ardp.201700204</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Abu Khalaf, R.; NasrAllah, A.; Jarrar, W.; Sabbah, D. Cholesteryl ester transfer protein inhibitory oxoacetamido-benzamide derivatives: Glide docking, pharmacophore mapping, and synthesis. Braz. J. Pharm. Sci., 2022, 58, 1-13.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Khalaf, R.A.; Awad, M.; Al-Qirim, T.; Sabbah, D. Synthesis and molecular modeling of novel 3,5-Bis(trifluoromethyl)benzylamino benzamides as potential CETP inhibitors. Med. Chem., 2022, 18(4), 417-426. doi: 10.2174/1573406417666210830125431 PMID: 34463228</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Khalaf, R.A.; Asaad, M.; Habash, M. Thiomethylphenyl benzenesulfonamides as potential cholesteryl ester transfer protein inhibitors: Synthesis, molecular modeling and biological evaluation. Curr. Org. Chem., 2022, 26(8), 807-815. doi: 10.2174/1385272826666220601150913</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Khalaf, R.A.; Shaiah, H.A.; Sabbah, D. Trifluoromethylated aryl sulfonamides as novel CETP inhibitors: Synthesis, induced fit docking, pharmacophore mapping and subsequent in vitro validation. Med. Chem., 2023, 19(4), 393-404. doi: 10.2174/1573406418666220908164014</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Schrödinger. Protein Preparation Wizard, Maestro, Macromodel, QPLD-dock, and Pymol; Schrödinger, LLC: Portland, OR, U.S.A., 2021, p. 97204.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Repasky, M.P.; Knoll, E.H.; Shelley, M.; Perry, J.K.; Shaw, D.E.; Francis, P.; Shenkin, P.S. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem., 2004, 47(7), 1739-1749. doi: 10.1021/jm0306430 PMID: 15027865</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Friesner, R.A.; Murphy, R.B.; Repasky, M.P.; Frye, L.L.; Greenwood, J.R.; Halgren, T.A.; Sanschagrin, P.C.; Mainz, D.T. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem., 2006, 49(21), 6177-6196. doi: 10.1021/jm051256o PMID: 17034125</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>The Molecular Operating Environment, Chemical Computing Group. Inc Montreal; Quebec, Canada, 2016.</mixed-citation></ref></ref-list></back></article>
